Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

This study has been terminated.
(Difficulty in recruitment.)
Sponsor:
Collaborator:
Amgen
Information provided by (Responsible Party):
Alexandra Kimball, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00477191
First received: May 18, 2007
Last updated: April 2, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: December 2014
  Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)